Researchers Recommend Wider Distribution Of First EUA-Cleared COVID-19 Test Using Smartphone Technology

BD has EUA for Veritor At-Home COVID-19 rapid antigen test using smartphone vision technology to interpret and digitally display results. Researchers at biotech firms and medical schools measure advantages of at-home use of rapid antigen tests over quantitative real-time polymerase chain reaction tests.

Professional doctor in a smartphone giving a consultation online and checking a radiography, telemedicine and healthcare concept, blank copy space

US emergency use authorizations for at-home COVID-19 tests reached smartphone technology for the first time while researchers say increasing OTC access to rapid antigen tests is key to accelerating detections of infections.

Becton, Dickinson and Co. on 25 August announced the Food and Drug Administration issued an EUA for the BD Veritor...

Welcome to Medtech Insight

Create an account to read this article

More from In Vitro Diagnostics

MCED Act Advances In US House Committees, Exact Sciences Cancerguard Poised To Benefit

 

The Nancy Gardner Sewell MCED Act has advanced in the US House, potentially allowing Medicare coverage for multi-cancer early detection tests. Exact Sciences is targeting FDA approval for its MCED test Cancerguard, launched in the US earlier this month.

Arima Genomics’ CEO Sets Sight On Replacing Standard Testing With 3D Genomics Lymphoma Assay

 
• By 

Arima Genomics launched its new Aventa Lymphoma test aimed at helping pathologists detect lymphomas missed by standard FISH analysis. Initially positioned as complementary technology, Arima hopes to become the new standard test.

Salient Bio Raises £2.35M For March 2026 Rollout Of At-Home IBD Microbiome Test

 

Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.

Government-Backed UK Network Enhances Access To Clinical Trials

 
• By 

The UK government expects that its new nation-wide network will enable companies to set up clinical trials more quickly and expand access to diverse patient populations across the National Health Service.

More from Diagnostics

Whistleblower Suit Against UnitedHealth Continues After Semler, Bard Settle Related Cases

 
• By 

Insurance firm UnitedHealth is facing allegations the company intentionally used an unreliable PAD screening method to increase its reimbursements under Medicare Advantage. Semler Scientific and Bard, which respectively made and manufactured the products in question, settled related cases for $37m.

‘Much-Needed Tool For Large Tissue Biopsy’: Resitu Medical’s Breast Device FDA Authorized

 

Resitu Medical has received FDA 510(k) authorization for the RESL09 breast cancer biopsy device. This handheld minimally invasive device excises tissue samples with diameters up to 9 mm and will first reach market in the US. The company plans to expand the tool’s clinical claims and core size range.

MCED Act Advances In US House Committees, Exact Sciences Cancerguard Poised To Benefit

 

The Nancy Gardner Sewell MCED Act has advanced in the US House, potentially allowing Medicare coverage for multi-cancer early detection tests. Exact Sciences is targeting FDA approval for its MCED test Cancerguard, launched in the US earlier this month.